NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance

Francesco Marampon, Silvia Codenotti, Francesca Megiorni, Andrea Del Fattore, Simona Camero, Giovanni Luca Gravina, Claudio Festuccia, Daniela Musio, Francesca De Felice, Valerio Nardone, Anna Natalizia Santoro, Carlo Dominici, Alessandro Fanzani, Luigi Pirtoli, Antonella Fioravanti, Vincenzo Tombolini, Sara Cheleschi, Paolo Tini

Research output: Contribution to journalArticle

Abstract

PURPOSE: Tumor cells generally exhibit higher levels of reactive oxygen species (ROS), however, when stressed, tumor cells can undergo a process of 'Redox Resetting' to acquire a new redox balance with stronger antioxidant systems that enable cancer cells to become resistant to radiation therapy (RT). Here, we describe how RT affects the oxidant/antioxidant balance in human embryonal (RD) and alveolar (RH30) rhabdomyosarcoma (RMS) cell lines, investigating on the molecular mechanisms involved.

METHODS: Radiations were delivered using an x-6 MV photon linear accelerator and their effects were assessed by vitality and clonogenic assays. The expression of specific antioxidant-enzymes, such as Superoxide Dismutases (SODs), Catalase (CAT) and Glutathione Peroxidases 4 (GPx4), miRNAs (miR-22, -126, -210, -375, -146a, -34a) and the transcription factor NRF2 was analyzed by quantitative polymerase chain reaction (q-PCR) and western blotting. RNA interference experiments were performed to evaluate the role of NRF2.

RESULTS: Doses of RT higher than 2 Gy significantly affected RMS clonogenic ability by increasing ROS production. RMS rapidly and efficiently brought back ROS levels by up-regulating the gene expression of antioxidant enzymes, miRNAs as well as of NRF2. Silencing of NRF2 restrained the RMS ability to counteract RT-induced ROS accumulation, antioxidant enzyme and miRNA expression and was able to increase the abundance of γ-H2AX, a biomarker of DNA damage, in RT-treated cells.

CONCLUSIONS: Taken together, our data suggest the strategic role of oxidant/antioxidant balance in restraining the therapeutic efficiency of RT in RMS treatment and identify NRF2 as a new potential molecular target whose inhibition might represent a novel radiosensitizing therapeutic strategy for RMS clinical management.

Original languageEnglish
Pages (from-to)881-893
Number of pages13
JournalJournal of Cancer Research and Clinical Oncology
Volume145
Issue number4
DOIs
Publication statusPublished - Apr 2019

Fingerprint

Alveolar Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Alveolar Epithelial Cells
Rhabdomyosarcoma
Oxidation-Reduction
Radiotherapy
Antioxidants
Reactive Oxygen Species
MicroRNAs
phospholipid-hydroperoxide glutathione peroxidase
Oxidants
Enzymes
Neoplasms
Particle Accelerators
RNA Interference
Photons
Catalase
DNA Damage
Superoxide Dismutase
Transcription Factors

Keywords

  • Antioxidants/metabolism
  • Cell Line, Tumor
  • Dose-Response Relationship, Radiation
  • Humans
  • MicroRNAs/biosynthesis
  • NF-E2-Related Factor 2/biosynthesis
  • Oxidation-Reduction/radiation effects
  • RNA, Small Interfering/administration & dosage
  • Radiation Tolerance
  • Reactive Oxygen Species/metabolism
  • Rhabdomyosarcoma, Alveolar/genetics
  • Rhabdomyosarcoma, Embryonal/genetics
  • Transfection
  • Up-Regulation/radiation effects

Cite this

NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. / Marampon, Francesco; Codenotti, Silvia; Megiorni, Francesca; Del Fattore, Andrea; Camero, Simona; Gravina, Giovanni Luca; Festuccia, Claudio; Musio, Daniela; De Felice, Francesca; Nardone, Valerio; Santoro, Anna Natalizia; Dominici, Carlo; Fanzani, Alessandro; Pirtoli, Luigi; Fioravanti, Antonella; Tombolini, Vincenzo; Cheleschi, Sara; Tini, Paolo.

In: Journal of Cancer Research and Clinical Oncology, Vol. 145, No. 4, 04.2019, p. 881-893.

Research output: Contribution to journalArticle

Marampon, F, Codenotti, S, Megiorni, F, Del Fattore, A, Camero, S, Gravina, GL, Festuccia, C, Musio, D, De Felice, F, Nardone, V, Santoro, AN, Dominici, C, Fanzani, A, Pirtoli, L, Fioravanti, A, Tombolini, V, Cheleschi, S & Tini, P 2019, 'NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance', Journal of Cancer Research and Clinical Oncology, vol. 145, no. 4, pp. 881-893. https://doi.org/10.1007/s00432-019-02851-0
Marampon, Francesco ; Codenotti, Silvia ; Megiorni, Francesca ; Del Fattore, Andrea ; Camero, Simona ; Gravina, Giovanni Luca ; Festuccia, Claudio ; Musio, Daniela ; De Felice, Francesca ; Nardone, Valerio ; Santoro, Anna Natalizia ; Dominici, Carlo ; Fanzani, Alessandro ; Pirtoli, Luigi ; Fioravanti, Antonella ; Tombolini, Vincenzo ; Cheleschi, Sara ; Tini, Paolo. / NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance. In: Journal of Cancer Research and Clinical Oncology. 2019 ; Vol. 145, No. 4. pp. 881-893.
@article{6c9732bfe2a94f85abbfc044ac0e00d4,
title = "NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance",
abstract = "PURPOSE: Tumor cells generally exhibit higher levels of reactive oxygen species (ROS), however, when stressed, tumor cells can undergo a process of 'Redox Resetting' to acquire a new redox balance with stronger antioxidant systems that enable cancer cells to become resistant to radiation therapy (RT). Here, we describe how RT affects the oxidant/antioxidant balance in human embryonal (RD) and alveolar (RH30) rhabdomyosarcoma (RMS) cell lines, investigating on the molecular mechanisms involved.METHODS: Radiations were delivered using an x-6 MV photon linear accelerator and their effects were assessed by vitality and clonogenic assays. The expression of specific antioxidant-enzymes, such as Superoxide Dismutases (SODs), Catalase (CAT) and Glutathione Peroxidases 4 (GPx4), miRNAs (miR-22, -126, -210, -375, -146a, -34a) and the transcription factor NRF2 was analyzed by quantitative polymerase chain reaction (q-PCR) and western blotting. RNA interference experiments were performed to evaluate the role of NRF2.RESULTS: Doses of RT higher than 2 Gy significantly affected RMS clonogenic ability by increasing ROS production. RMS rapidly and efficiently brought back ROS levels by up-regulating the gene expression of antioxidant enzymes, miRNAs as well as of NRF2. Silencing of NRF2 restrained the RMS ability to counteract RT-induced ROS accumulation, antioxidant enzyme and miRNA expression and was able to increase the abundance of γ-H2AX, a biomarker of DNA damage, in RT-treated cells.CONCLUSIONS: Taken together, our data suggest the strategic role of oxidant/antioxidant balance in restraining the therapeutic efficiency of RT in RMS treatment and identify NRF2 as a new potential molecular target whose inhibition might represent a novel radiosensitizing therapeutic strategy for RMS clinical management.",
keywords = "Antioxidants/metabolism, Cell Line, Tumor, Dose-Response Relationship, Radiation, Humans, MicroRNAs/biosynthesis, NF-E2-Related Factor 2/biosynthesis, Oxidation-Reduction/radiation effects, RNA, Small Interfering/administration & dosage, Radiation Tolerance, Reactive Oxygen Species/metabolism, Rhabdomyosarcoma, Alveolar/genetics, Rhabdomyosarcoma, Embryonal/genetics, Transfection, Up-Regulation/radiation effects",
author = "Francesco Marampon and Silvia Codenotti and Francesca Megiorni and {Del Fattore}, Andrea and Simona Camero and Gravina, {Giovanni Luca} and Claudio Festuccia and Daniela Musio and {De Felice}, Francesca and Valerio Nardone and Santoro, {Anna Natalizia} and Carlo Dominici and Alessandro Fanzani and Luigi Pirtoli and Antonella Fioravanti and Vincenzo Tombolini and Sara Cheleschi and Paolo Tini",
year = "2019",
month = "4",
doi = "10.1007/s00432-019-02851-0",
language = "English",
volume = "145",
pages = "881--893",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - NRF2 orchestrates the redox regulation induced by radiation therapy, sustaining embryonal and alveolar rhabdomyosarcoma cells radioresistance

AU - Marampon, Francesco

AU - Codenotti, Silvia

AU - Megiorni, Francesca

AU - Del Fattore, Andrea

AU - Camero, Simona

AU - Gravina, Giovanni Luca

AU - Festuccia, Claudio

AU - Musio, Daniela

AU - De Felice, Francesca

AU - Nardone, Valerio

AU - Santoro, Anna Natalizia

AU - Dominici, Carlo

AU - Fanzani, Alessandro

AU - Pirtoli, Luigi

AU - Fioravanti, Antonella

AU - Tombolini, Vincenzo

AU - Cheleschi, Sara

AU - Tini, Paolo

PY - 2019/4

Y1 - 2019/4

N2 - PURPOSE: Tumor cells generally exhibit higher levels of reactive oxygen species (ROS), however, when stressed, tumor cells can undergo a process of 'Redox Resetting' to acquire a new redox balance with stronger antioxidant systems that enable cancer cells to become resistant to radiation therapy (RT). Here, we describe how RT affects the oxidant/antioxidant balance in human embryonal (RD) and alveolar (RH30) rhabdomyosarcoma (RMS) cell lines, investigating on the molecular mechanisms involved.METHODS: Radiations were delivered using an x-6 MV photon linear accelerator and their effects were assessed by vitality and clonogenic assays. The expression of specific antioxidant-enzymes, such as Superoxide Dismutases (SODs), Catalase (CAT) and Glutathione Peroxidases 4 (GPx4), miRNAs (miR-22, -126, -210, -375, -146a, -34a) and the transcription factor NRF2 was analyzed by quantitative polymerase chain reaction (q-PCR) and western blotting. RNA interference experiments were performed to evaluate the role of NRF2.RESULTS: Doses of RT higher than 2 Gy significantly affected RMS clonogenic ability by increasing ROS production. RMS rapidly and efficiently brought back ROS levels by up-regulating the gene expression of antioxidant enzymes, miRNAs as well as of NRF2. Silencing of NRF2 restrained the RMS ability to counteract RT-induced ROS accumulation, antioxidant enzyme and miRNA expression and was able to increase the abundance of γ-H2AX, a biomarker of DNA damage, in RT-treated cells.CONCLUSIONS: Taken together, our data suggest the strategic role of oxidant/antioxidant balance in restraining the therapeutic efficiency of RT in RMS treatment and identify NRF2 as a new potential molecular target whose inhibition might represent a novel radiosensitizing therapeutic strategy for RMS clinical management.

AB - PURPOSE: Tumor cells generally exhibit higher levels of reactive oxygen species (ROS), however, when stressed, tumor cells can undergo a process of 'Redox Resetting' to acquire a new redox balance with stronger antioxidant systems that enable cancer cells to become resistant to radiation therapy (RT). Here, we describe how RT affects the oxidant/antioxidant balance in human embryonal (RD) and alveolar (RH30) rhabdomyosarcoma (RMS) cell lines, investigating on the molecular mechanisms involved.METHODS: Radiations were delivered using an x-6 MV photon linear accelerator and their effects were assessed by vitality and clonogenic assays. The expression of specific antioxidant-enzymes, such as Superoxide Dismutases (SODs), Catalase (CAT) and Glutathione Peroxidases 4 (GPx4), miRNAs (miR-22, -126, -210, -375, -146a, -34a) and the transcription factor NRF2 was analyzed by quantitative polymerase chain reaction (q-PCR) and western blotting. RNA interference experiments were performed to evaluate the role of NRF2.RESULTS: Doses of RT higher than 2 Gy significantly affected RMS clonogenic ability by increasing ROS production. RMS rapidly and efficiently brought back ROS levels by up-regulating the gene expression of antioxidant enzymes, miRNAs as well as of NRF2. Silencing of NRF2 restrained the RMS ability to counteract RT-induced ROS accumulation, antioxidant enzyme and miRNA expression and was able to increase the abundance of γ-H2AX, a biomarker of DNA damage, in RT-treated cells.CONCLUSIONS: Taken together, our data suggest the strategic role of oxidant/antioxidant balance in restraining the therapeutic efficiency of RT in RMS treatment and identify NRF2 as a new potential molecular target whose inhibition might represent a novel radiosensitizing therapeutic strategy for RMS clinical management.

KW - Antioxidants/metabolism

KW - Cell Line, Tumor

KW - Dose-Response Relationship, Radiation

KW - Humans

KW - MicroRNAs/biosynthesis

KW - NF-E2-Related Factor 2/biosynthesis

KW - Oxidation-Reduction/radiation effects

KW - RNA, Small Interfering/administration & dosage

KW - Radiation Tolerance

KW - Reactive Oxygen Species/metabolism

KW - Rhabdomyosarcoma, Alveolar/genetics

KW - Rhabdomyosarcoma, Embryonal/genetics

KW - Transfection

KW - Up-Regulation/radiation effects

U2 - 10.1007/s00432-019-02851-0

DO - 10.1007/s00432-019-02851-0

M3 - Article

C2 - 30701326

VL - 145

SP - 881

EP - 893

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 4

ER -